

SAFETY & QUALITY OF MEDICINES GROUP

Meeting

Thursday 26th October 2006 Time: 9.30am to 2.30pm

Attendees

Kevin Hague (Chair)	Gillian Bohm (MOH)
Frances McClure (GP)	Beth Loe (Project Manager)
Marilyn Crawley (Waitemata)	Mary Seddon (CMDHB)
Avril Lee (WDHB)	Tim Maling (C&CDHB)
Teresa Sullivan (ACC)	Peter Moodie (PHARMAC)

Invited

Bronwyn Clark (Pharmacy Council)

Minutes

Item	Topic/agenda	Notes/comments	Action Required
1.	Apologies	Sharron Cole, Peter Black, Adam McRae, Nigel Miller, Elizabeth Plant, Emil Schmitt	
2.	Welcome to Kevin Hague	Other changes to membership of the group were discussed <ul style="list-style-type: none"> • Nigel Miller has agreed to represent Canterbury DHB in place of Jane Vella Brincat • Emil Schmitt has tendered his resignation and has suggested Deb Lawry replace him, Nurse Director for Womens & Child Health Otago DHB • Sharron Cole is unable to attend meetings on the last Thursday of the month and if the meeting day can not be changed will resign 	
3.	Minutes of previous meeting	<ul style="list-style-type: none"> • Agreed • An advert for “Expressions of interest in becoming a member” is included in the next addition of the newsletter • Need for international classification system for the significance of drug interactions – follow up at next meeting 	<ul style="list-style-type: none"> • Classification system for drug interaction significance – Dec meeting agenda (Beth)
4.	PHARMAC consultation on diltiazem and colchicine as part of consultation document issued on 22.9.06	<ul style="list-style-type: none"> • Feedback our concerns regarding the no. of funded diltiazem preparations • Feedback the current national approach to colchicine prescribing i.e. 0.5mcg and to choose a blister packed preparation if that option is available to reduce the risk of accidental overdose • Packaging is a general issue that needs to be raised with Medsafe 	<ul style="list-style-type: none"> • Diltiazem (Mary) • Colchicine (Beth) • Raise packaging issues at MARC/Medsafe (Frances/Tim)
9.	Bronwyn Clark, Pharmacy Council	<ul style="list-style-type: none"> • Council produce a newsletter every quarter and happy to include items from the group • Newsletter reaches all registered pharmacists. Pharmacy Guild produce a weekly newsletter but only reaches Guild members • Ensuring that competency standards exist for pharmacists providing medicine use review services 	<ul style="list-style-type: none"> • Training in systems failures and dealing with errors was an important area for the group

		<ul style="list-style-type: none"> Ensuring that an understanding of systems failures and how to deal with errors is included in the intern training and registration competency standards 	
5.	National Medicines Policy framework	<ul style="list-style-type: none"> Difficult to provide feedback on this brief document in its current form Nothing about the safety or standardisation of systems in practice Need to have quality systems as a theme throughout the document Overuse/under use concepts not included Would it be possible to have a draft of the final document pre-release to comment on? 	<ul style="list-style-type: none"> Follow up with Ministry (Beth)
6.	ANZTPA draft documents on product vigilance	<ul style="list-style-type: none"> No detail in the document for both devices and medicines What process would there be around unlicensed products? At the moment allergies can be linked to a patient's NHI in NZ, will this facility still be available? Need to put in comments about post marketing surveillance and problems with look alike, sound alike names Two members have been invited to a focus meeting in Auckland on November 9th MARC have a meeting with ANZTPA next week about this Basic concept good, needs comments about labelling and packaging 	<ul style="list-style-type: none"> Attend meeting in Auckland (Beth, Marilyn) Find out if other focus meetings nationally (Beth) Suggested alert on reporting adverse events to CARM
7.	Unfilled hospital discharge prescriptions due to inequitable funding issues	<ul style="list-style-type: none"> This has been raised at the MOH by more than one DHB Ministry have replied to letter Marilyn sent about this problem, unsure of detail of response Are we able to quantify the problem Is it part of medicines reconciliation 	<ul style="list-style-type: none"> Marilyn to circulate Ministry response to group (Marilyn) Identify if we can quantify problem although it is unlikely that we can (Beth) Letter to PHONZ highlighting the issue to them (Beth)
	PreMec proposal for transfer of funds to group	<ul style="list-style-type: none"> PreMec is a registered charity and to transfer their funds would be expensive Suggestion that PreMec would cease to exist in its present form and SQM would in effect take over their structure i.e. their incorporated society status, money, committee functions etc PreMec final AGM 8/11/06 	<ul style="list-style-type: none"> Talk to DHBNZ and PreMec about the proposal (Kevin)
8.	EpiQual national meeting	<ul style="list-style-type: none"> On hold at the moment but will happen Medicines reconciliation still likely to be one of WHO High 5 topics How can medicines reconciliation be advanced, what is currently happening around the country, % patients that it happens to etc. CMDHB running pilots at the moment and evaluation will be available in 3 months or so Can we re-do Elizabeth & Marilyn stock take of what is happening nationally about e pharmacy and the timelines involved 	<ul style="list-style-type: none"> Provide links to CMDHB documentation (Mary) Look at how it is done at next meeting National stock takes of medicines reconciliation (need a volunteer) National stock takes of e pharmacy (need a volunteer)
10.	High Risk Medicines	<ul style="list-style-type: none"> 	
10.i	Potassium &	<ul style="list-style-type: none"> Many of the pre-mixes still not registered 	<ul style="list-style-type: none"> Talk to Dwayne about contact

	heparin pre mixes	<ul style="list-style-type: none"> • Need to send out an updated potassium alert when they are registered 	with Medsafe re registration (Kevin)
10. ii	Warfarin	<ul style="list-style-type: none"> • Some feedback to PHARMAC about DVD as opposed to video • BPAC have produced a very good booklet about INR testing – to be included in the toolkit 	<ul style="list-style-type: none"> • Quotes for toolkit (Beth, Avril)
10.iii	Heparin	<ul style="list-style-type: none"> • Still working on heparin • Some changes to LMWH alert • Discuss further at next meeting 	<ul style="list-style-type: none"> • Update LMWH alert and send out (Beth)
10.iv	Morphine	<ul style="list-style-type: none"> • Postpone to next meeting 	<ul style="list-style-type: none"> • Re-draft alert (Marilyn)
10.v	Intravenous infusions	<ul style="list-style-type: none"> • Contact details to go on alert? not been done previously • Take out definition • Send out for wider consultation • Feedback invited on draft audit tool based on NPSA audit tool • Discussed need for a Grasby pump alert 	<ul style="list-style-type: none"> • Take draft alert to MAC at CMDHB (Mary) • Send out for wider consultation (Beth) • Finish audit sheet (Beth, Marilyn) • Take proposed audit to quality managers group (Gillian) • Grasby pump alert (Need a volunteer)
10vi	Good Prescribing Practice	<ul style="list-style-type: none"> • Alert with PHARMAC to be put into final format 	<ul style="list-style-type: none"> • Circulate completed alert for final comments (Beth)
10. vii	IT cytotoxic injection	<ul style="list-style-type: none"> • Feedback from SIG group of NZHPA has gone to NZHPA executive prior to coming to group 	<ul style="list-style-type: none"> • Circulate re-drafted guideline to the group when available (Beth)
10. viii	Colchicine	<ul style="list-style-type: none"> • Included in Pharmacy Council newsletter and has already been included in Pharmaceutical Society newsletter • Feedback to PHARMAC 	<ul style="list-style-type: none"> • Feedback to PHARMAC (Beth)
10.ix	Amiodarone	<ul style="list-style-type: none"> • Extent of the problem of prolonged continuation of loading dose based on data from WDHB and Kowhai PHO is that annually between 6 and 25% of patients discharged on amiodarone are discharged on a loading dose. From Kowhai PHO research, about 25% of the patients discharged on loading doses unintentionally remain on the loading dose although this was corrected relatively quickly • Another issue identified was that the monitoring of patients on long term amiodarone was not being carried out by either 1y or 2y care • Problem needs highlighting but not as an alert 	<ul style="list-style-type: none"> • Identify if Cardiac Society see this as an issue (Beth) • Highlight to Pharmacist Facilitators (Beth) • Include it as our item in the next BPAC publication (Beth)
10.x	Oral Methotrexate	<ul style="list-style-type: none"> • Re-start alert process 	<ul style="list-style-type: none"> • Draft alert needed (Beth)
11.	Renal drug dosing	<ul style="list-style-type: none"> • Should decisions be based on eGFR or Cockcroft & Gault creatinine clearance estimation • eGFR regularly available so start from there 	<ul style="list-style-type: none"> • Draft alert for next meeting (Tim)
12.	Information technology		

12.i.	Toniq dispensing software	<ul style="list-style-type: none"> • Toniq, first 3 drugs in draft format • Will the other dispensary software provider (Lots) be willing to provide the same warnings in their system 	<ul style="list-style-type: none"> • Continue to draft warnings (Beth) • Contact Lots (Beth)
12.ii	Bar coding	<ul style="list-style-type: none"> • Consultation document being written for the Minister by a group headed by the ministry 	
13.	National Drug Chart	<ul style="list-style-type: none"> • Sent out for consultation • Some DHBs requested an extension, until middle of November • Feedback generally positive with support for the concept and willingness to accept changes so that a national chart can be introduced • Some consistent messages about what could be changed to improve the chart 	<ul style="list-style-type: none"> • Collate feedback for next meeting (Beth)
14.	ACC research funding	<ul style="list-style-type: none"> • Research strategy currently being reviewed • Clearer guidelines being developed on the areas of research that will be considered • The strategy has to go out for consultation • Next research round Feb/Mar 	<ul style="list-style-type: none"> • Consider what research proposals the group should make (All)
	Date of next meeting	<ul style="list-style-type: none"> • December 7th in Auckland 	